established constitution, published in 2011 by the Department of Health. Besides the constitution, the Health and Social Care Act of 2012, under which the Clinically Commissioning Groups were established, regulates the NHS budget. The NHS provides assistance to these CCGs through Commissioning Support Units (CSUs), in addition to providing clinicians, as well as payers, an outlook on which practices are good for a particular therapeutic area.
The Act also brought about significant legal changes, such as the implementation of the Healthwatch network, to reinforce the voice of the consumer, and the Public Health England, to protect and improve the nation's health and wellbeing, and reduce health inequalities. This act also oriented the competition in the healthcare market towards the interest of the patients, by establishing Monitor, which issues licenses to regulate providers of NHS services. Now in the UK pharmaceutical companies have to operate alongside many local groups, each with different unmet needs and value definitions. Thus, companies need to first understand the needs of the stakeholders and deliver healthcare solutions to the population of that area accordingly.
The NHS is not only concerned with price regulation, but also with the health insurance system of the region. Healthcare is covered by the NHS for the majority of the population, entirely funded by taxes. Besides the government-funded public healthcare insurance, certain private companies, which hold minor sectors, also cover residents, offering additional benefits. In order to involve local health councils and authorities to join the NHS and contribute to the enhancement of social welfare and healthcare, in 2015 the UK government allocated £ 2.7 billion and £ 200 million, respectively, to these bodies. The government also established Integrated Care and Support Exchange (ICASE), which is aimed at bringing expertise from different parts of the nation to contribute to the goal of developing integrated models of care and support in different places, to enhance the degree of public healthcare in the respective locations.
Pathways of Market Access
As seen above, the UK government exercises control over healthcare, insurance, and pharmaceuticals to a great extent, ensuring and safeguarding the interest of consumers and patients alike. The market access of pharmaceutical companies in the UK involves several processes, but it is mainly related to government regulations, pricing and reimbursement strategies. Figure 1 shows the common steps involved in enabling market access on the part of any pharmaceutical company within the UK.
Pharmaceutical Regulation
The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department of Health. The MHRA has three centres: 1) the Clinical Practice Research Datalink (CPRD), which is a data research service that provide anonymized NHS clinical data, 2) the National Institute for Biological Standards and Control (NIB-SC), which has been established to standardize and control biological medicines, and 3) the MHAR, which regulates medicines, medical devices and blood components for transfusion, according to the standards set to ensure their safety, efficacy and quality. The degree of control to be exercised over the supply of a medicinal product depends on the legal classification the latter falls into. There are three such categories, namely: 1) Prescription, which includes the drugs that must be dispensed only by a licensed facility, and upon a prescription written by a health professional, 2) Pharmacy, which includes the drugs that can be bought under the supervision of a pharmacist, and 3) General sales list, which includes the drugs available at retail stores.
Besides the need of an appropriate license for the distribution of medicines, drugs must meet the minimum production standards, as determined by the Good Manufacturing Practices (GMP). The MHRA is responsible for carrying out the inspection in the manufacturing and distribution sites, to ensure the adherence to GMP guidelines, and for issuing GMP ratings, depending upon the compliance report, the information regarding the previous inspection history, and any changes in the organization. MHRA works alongside the EMA (European Medicine Agency) to provide recommendations for the various medicines that are submitted for approval. However, Brexit has changed the dynamics between EMA and MHRA, and this might lead to a different process of drug approval and access in the UK. Furthermore, the agency aims at ensuring that the applicable standards are met. The regulatory dilemma arisen post-Brexit poses implications of serious nature on the UK pharmaceutical industry, since UK lost EMA, and the influence of MHRA is also perceived as decreasing.
Pharmaceutical Pricing
Pharmaceutical pricing has changed since 2009, after the Pharmaceutical Price Regulation Scheme (PPRS) was enforced by the NHS. In the UK, the NHS is the main buyer of pharmaceutical products, either branded, innovative drugs/biologics or generic drugs/ biosimilars. To finalize the price of these prescription drugs, the manufacturers discuss matters with the government, and these discussions are different for innovative and generic drugs. The price of branded drugs is controlled by PRRS, which was brought into effect by an agreement between the pharmaceutical industry and the government. The payment percentage of PPRS is also set by an agreement between the pharmaceutical industry and the government, to bring stability to the stakeholders -to plan investment strategies -and to support NHS funding, in order to provide health services, respectively. The PPRS for 2017 has been revised and set at 4.75%. The scheme regulates the profits pharmaceutical companies can make on the sales of their drugs to the NHS, and includes a clause for a renegotiation to be implemented every 5 years. NICE assesses the clinical efficacy and cost-effectiveness of each drug on behalf of the NHS for England, Wales, and Ireland, and then recommends a fair price to the NHS. Since the budget allocation with the NHS for healthcare is fixed, the price of new treatments comes at the expense of other treatments. Thus, the NHS is always looking for effective and safe generics and biosimilars for the treatment of various diseases.
Pharmaceutical Reimbursement
The healthcare system in the UK is largely public, with around 80% of funds sourced from taxes, 12% from insurance, and the rest from miscellaneous charges and sources as depicted in Figure 2 .
In terms of reimbursement, the process in the UK is quite different from the other European countries. The country has little direct pricing control, since the originator drug price is set by the PPRS and the drug price is reimbursed by the NHS to the contractors under the Community Pharmacy Contractual Framework. However, the reimbursement prices to be dispensed by the NHS are determined by the Secretary of the State, with the reimbursements being issued in the form of a combinations of allowances, medicine margins, and fees. The medicine margin, as achieved by a contractor, is assessed by the Department of Health and Pharmaceutical Services Negotiating Committee. Apart from the price set, there is a matter of spending through patient co-payment as a form of prescription charges, which is a claw-back system operated by the UK government for government hospitals and community pharmacies [15] .
Mapping and Structure of Decision Makers
The Code of Practice for Pharmaceutical Industry was laid out by the Association of the British Pharmaceutical Industry (ABPI), to ensure the appropriate promotion of drugs to health professionals and other decision makers. The code incorporates the principles set out in the codes of different organizations around the world (i.e., IFPMA -International prominent is NIHR Health Technology Assessment Programme, which assesses drugs through conventional HTAs through evidence synthesis and modeling, and generates evidence of effectiveness through cohort studies. Apart from this organization, the Multidisciplinary Assessment of Technology Centre for Healthcare (MATCH) also plays a HTA role, in collaboration with the NHS, to assess various industrial partners. The main four themes that MATCH organizes for assessment are shown in Figure 3 . The PPRS is a voluntary agreement between the Government and the pharmaceutical industry. The current scheme runs for five years from January 2014. Companies that choose not to join the PPRS are covered by the Statutory Scheme for Pricing of Branded Medicines. In this scheme, a 15% cut is applied on the NICE list price, and is subject to revision. The scheme does not include the companies that have sales lower than € 5 million and the products which have been launched after December 2013 are not allowed for discounts.
Challenges and Catalyzers for Market Access

Challenges
Marketing consultant PharmaBase surveyed 27 European pharmaceutical companies (while the UK was still a part of the Community), which included 5 top Pharma companies of the region, and the results suggested that the greatest challenge for an effective market access strategy was local decision making, something that would change with changing territory. Another challenge revealed by the survey concerned the NHS's constant drive to increase cost-savings in the healthcare sector, driving up negotiations on discounts and reimbursement. QALY was also seen as a hurdle, since it was considered a blunt tool to measure the value of a drug. Even though QALY measures cost-effectiveness through clinical benefit for the patient, it fails to look into the impact the drug might have on caregivers and family members, as well as on the wider social costs and benefits for the general population or the NHS. For example, four of AstraZeneca's drugs were voted as being cost-effective for moderate to severe Alzheimer, but not so effective for mild Alzheimer. However, many argue that providing drugs in a mild setting helps slow the progression to a moderate and severe condition, and helps increase the quality of life of the patient, as well as being beneficial from the caregiver's perspective.
Catalysts
The main processes that prove to be a driving force for an effective market access strategy include an effective pricing strategy, accurate health outcomes/health technology assessments (HTAs), as well as an efficient milestone management of drug candidates by the companies. Additionally, stakeholder mapping, the issues regarding the preparation for market access and patient advocacy are also factors that help create a successful market strategy in the pharmaceutical sector.
Successful Market Access Strategies
AstraZeneca developed an innovative drug -osimertinib -to treat patients suffering from a type of lung cancer characterized by high unmet medical needs. Using the Early Access to Medicine Scheme (EAMS), AstraZeneca could enter the market sooner. The scheme directly helped 22 UK patients benefit from this decision, and the marketing approval was granted to the drug only eight months after its submission to EMA for authorization. The drug, thus, reached the patients only 3 years after it was first tested on humans, providing a great example of an effective development and marketing strategy by AstraZeneca.
Similarly, Abbvie's drug glecaprevir/pibrentasvir (G/P), was the first treatment for HCV to be approved through EAMS. The approval was granted in May 2017, and UK patients would have early access to the drug while it is being reviewed by EMA for potential authorizations in other countries of the European Union and the European Economic Area.
Another non-cancer drug to be approved through EAMS is dupixent by Sanofi, for the treatment of atopic dermatitis. Through EAMS, Sanofi received the NICE recommendation and MHRA approval in 30 days, instead of the standard 3-month procedure. These are two examples of successful strategies to gain pre-authorization approval and accelerated pricing and reimbursement approval. These were possible because the company had decided to develop therapies that had a high unmet medical need in the UK.
Advances in the Near Future
The challenges and drivers, along with the processes and organizational policies in the UK pharmaceutical industry, suggested that there is no 'one-size-fits-all' process that a company can undertake to implement price and reimbursement schemes for their different products. The highly localized and customizable processes for any drug in different setting urged the companies to develop their market access strategies in order to examine every process in detail beforehand, and be ready for any consequences from any stakeholder. The market access management has become a great need for the future, and the companies need to implement market access strategies, in order to create better prospects. Moreover, they have to increase their engagement with government bodies as well as patient organizations, GPs, chief pharmacists and patients. Companies also need to create robust methodologies, have transparent testing systems, implement post-launch trials and improve their patient-awareness processes, to promote their products among each stakeholder, in order to increase sales and profit, keeping in mind the fact that drug development and manufacturing require huge R&D expenses.
